With its twice-yearly dosing, the siRNA-based drug might lead to better compliance with treatment. Still, cost is an issue.

Researchers evaluated real-world data to extend treatment intervals, maintain BCVA, and achieve macular fluid resolution ...

Patients with moderate to severe chronic spontaneous urticaria that were antihistamine-resistant to omalizumab experienced ...

Dr. Cathy Eng discusses data that led to the FDA approval of Braftovi and Erbitux plus chemo for metastatic colorectal cancer ...